A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

NCT ID: NCT05371652

Last Updated: 2025-02-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 241 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-19
• Study Completion Date: 2024-02-06

Brief Summary

This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine

Conditions

Acute Migraine

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Rimegepant 75mg Orally Disintegrating Tablets (ODT)

One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day)

Group Type: EXPERIMENTAL

Rimegepant 75mg Orally Disintegrating Tablets (ODT)

Intervention Type: DRUG

One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack

Interventions

Rimegepant 75mg Orally Disintegrating Tablets (ODT)

One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

At least a one-year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition beta version, including the following:

• Age of onset of migraines prior to 50 years of age
• Migraine attacks, on average, lasting 4 - 72 hours if untreated
• 6-18 migraine attacks of moderate or severe intensity per month within the last 3 months prior to the Screening Visit
• 6 or more migraine days requiring treatment during Observation Phase
• Ability to distinguish migraine attacks from tension/cluster headaches
• Subjects on prophylactic migraine medication are permitted to remain on therapy if the dose has been stable dose for at least 2 months prior to the Baseline Visit, and the dose is not expected to change during the course of the study. subjects who previously discontinued prophylactic migraine medication must have done so at least 5 half-lives of the prophylactic medication prior to the Screening Visit
• Subjects with contraindications for use of triptans may be included provided they meet all other study entry criteria

Age and Reproductive Status:

• Male or female subjects ≥ 18 years
• Women of childbearing potential (WOCBP) must voluntarily use 1 acceptable methods of contraception to avoid pregnancy and to minimize the risk of pregnancy from signing of informed consent through 28 days after study drug administration. WOCBP is defined in Section 12.3. No contraception methods are required for male subjects in this study.

Exclusion Criteria

Target Disease Exclusion:

• Subjects has a history of basilar migraine with brain stem aura or hemiplegic migraine

Medical History and Comorbidities:

• History of HIV disease
• Current evidence of poorly controlled, unstable, or recently diagnosed cardiovascular or cerebrovascular disease such as ischemic heart disease, coronary vasospasm, and cerebral ischemia. Myocardial infarction (MI), acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), cardiac surgery, stroke, or transient ischemic attack (TIA) during 6 months prior to screening
• Poorly controlled hypertension (high blood pressure) or poorly controlled diabetes (but subjects with stable hypertension and/or diabetes for at least 3 months prior to screening may be included in the study). Blood pressure greater than 150 mmHg systolic or 100 mmHg diastolic after 10 minutes of rest is exclusionary
• Subjects with a current diagnosis of major depression or a major depressive episode within the last 12 months, other pain syndromes, psychiatric disorders, dementia, or significant neurological disorders (other than migraine) that, in the opinion of the investigator, might interfere with study assessments
• History of gastric or small intestinal surgery (including gastric bypass, gastric banding, gastric sleeve, gastric water ball, etc.) or diseases resulting in malabsorption
• Subject has a history or diagnosis of Gilibert's Syndrome or any other active hepatic or biliary disorder
• History or presence of significant and/or unstable medical conditions (e.g., history of congenital heart disease or cardiac arrhythmia, known suspected infection, hepatitis B or C or neoplasm) that, in the opinion of the investigator, would expose the subjects to undue risk of a significant adverse events (AE) or interfere with the assessment of safety or effectiveness during the trial
• History or evidence of alcohol or drug abuse within the past 12 months, or treatment for alcohol or drug abuse, or meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for any significant substance abuse disorder within the past 12 months prior to the Screening Visit
• Subjects should be excluded if they have a positive drug screen for drugs of abuse and are considered medically significant by the investigator, would compromise subject safety, or interfere with the interpretation of study results. In addition:
• Subjects with detectable levels of cocaine, amphetamines, and phencyclidine in drug abuse screening need to be excluded.

Subjects who are positive for amphetamines on the urine drug screen may have their urine samples evaluated for further analysis at the investigator's discretion to rule out a false positive result

• Subjects with detectable levels of marijuana during substance abuse screening may not be excluded if they do not meet DSMV criteria for substance abuse or dependence in the subject's opinion as documented by the investigator, and a positive result does not signal a clinical condition that would impact the subject safety or interpretation of the study results
• Diagnosis of hematologic or solid malignancy within 5 years prior to screening. Subjects with a history of localized basal cell or squamous cell skin cancer may be included in the study if they are cancer-free prior to the screening visit for this study
• Subjects with a current diagnosis of schizophrenia, major depression requiring treatment with atypical antipsychotics, bipolar disorder or borderline personality disorder
• Body mass index (BMI) ≥ 35 kg/ m2
• Subjects with a history of gallstones or cholecystectomy
• Use of St. John's Wort, products containing St. John's Wort, Coltsfoot root, or extracts within 14 days prior to the baseline visit
• Use of narcotic drugs such as opioids (e.g., morphine, codeine, oxycodone, and hydrocodone) within 2 days prior to the baseline visit.

Allergy and Adverse Reactions:

*. History of drug or other allergy that, in the opinion of the investigator, would make the subject unsuitable for participation in the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

The Second Hospital of Anhui Medical University

Hefei, Anhui, China

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

The First Affiliated hospital of Xiamen University

Xiamen, Fujian, China

Hainan General Hospital

Haikou, Hainan, China

Hebei General Hospital

Shijiazhuang, Hebei, China

Renmin Hospital Of Wuhan University

Wuhan, Hubei, China

Wuhan Third Hospital

Wuhan, Hubei, China

Changsha Central Hospital

Changsha, Hunan, China

Xiangya Hospital Central South University

Changsha, Hunan, China

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

The Second Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

The Second Hospital of Jilin University

Changchun, Jilin, China

The Second Hospital of Jilin University

Changchun, Jilin, China

General Hospital of Northern Theater Command

Shenyang, Liaoning, China

Shaanxi Provincial People' Hospital

Xi'an, Shaanxi, China

The First Affiliated Hospital of Xi'an Medical University

Xi'an, Shaanxi, China

Yan'an University Xianyang Hospital Co., Ltd

Xianyang, Shaanxi, China

LiaoCheng People's Hospital

Liaocheng, Shandong, China

Tongji Hospital of Tongji University

Shanghai, Shanghai Municipality, China

West China Hospital of Sichuan University

Chengdu, Sichuan, China

The Second Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

The Second Affiliated hospital of Kunming Medical University

Kunming, Yunnan, China

Peking University People's Hospital

Beijing, , China

Guangzhou First People's Hospital

Guangzhou, , China

Countries

China

References

Zhang M, Guo A, Wu J, Wang H, Zhang Y, Dong H, Liu J, Zhang B, Guo H, Yu T, Lu Z, Ma L, Fountaine RJ, Pixton GC, Zhong Q, Han X, Yu S. Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China. Cephalalgia. 2025 Oct;45(10):3331024251371686. doi: 10.1177/03331024251371686. Epub 2025 Oct 9.

Reference Type: DERIVED

PMID: 41066271 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://pmiform.com/clinical-trial-info-request?StudyID=BHV3000-318

To obtain contact information for a study center near you, click here.

Other Identifiers

C4951018

Identifier Type: OTHER

Identifier Source: secondary_id

BHV3000-318

Identifier Type: -

Identifier Source: org_study_id